Tom Cotton (R-AR)

PILLS Act

S. 1891 · Senate bill Taxation

A Republican bill with no cosponsors

Last activity — Read twice and referred to the Committee on Finance.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

  1. Introduced
  2. In Committee

What this bill would do

This bill, known as the "PILLS Act," seeks to amend the Internal Revenue Code of 1986 to encourage the production of generic drugs and biosimilars within the United States. It establishes a production credit for taxpayers manufacturing eligible components and selling them to unrelated persons. Additionally, the bill creates an investment credit for taxpayers building qualified facilities for the production of these medicines. The production credit includes potential bonuses for domestic content and features a phase-out period starting after 2030. The investment credit applies to qualified property placed in service before the end of 2028.

Yes· 3 of 11

  • Scored +6

    Would business owners be better off under this?

    The investment and production credits provide significant incentives for pharmaceutical business owners.

  • Scored +6

    Does this lower the price of prescription medicines?

    Increasing domestic production of generics and biosimilars aims to lower the costs of essential medicines.

  • Scored +5

    Would households on low incomes be better off under this?

    Reduced drug costs provide significant economic relief to low-income families.

The opposite

No question was scored the opposite.